miR-378a-3p sensitizes ovarian cancer cells to cisplatin through targeting MAPK1/GRB2 - 20/09/18
pages | 8 |
Iconographies | 6 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | Downregulation of miR-378a-3p is closely correlated with poor prognosis of OC patients. |
• | miR-378a-3p acts as a tumor suppressor to sensitize OC cells to cisplatin. |
• | MAPK1 and GRB2 are two target mRNAs of miR-378a-3p in OC cells. |
• | MAPK1 and GRB2 reverses the effects of miR-378a-3p on chemosensitivity of OC cells. |
Abstract |
Ovarian cancer has gradually become one of the commonest gynecological tumor in the world. Although various therapies have been developed by researchers, the chemoresistance of ovarian cancer is still a huge challenge. MircroRNAs (miRNAs) have been widely studied due to their anti-oncogenic functions. MiR-378a-3p has been reported to sensitize breast cancer cells to chemotherapy. Here, we hypothesized that miR-378a-3p is a potential chemosensitizer in ovarian cancer. Firstly, miR-378a-3p was uncovered to down-regulated in ovarian cancer tissues and cell lines through using qRT-PCR analysis and northern blot analysis. According to the result of Kaplan Meier analysis, low expression of miR-378a-3p is closely associated with unfavorable prognosis of ovarian cancer patients. Subsequently, gain-of function assays indicated that miR-378a-3p suppressed cell proliferation and promoted cell apoptosis. Moreover, miR-378a-3p was found to enhance cisplatin sensitivity of ovarian cancer cells. Mechanism investigations suggested that MAPK1 and GRB2 are two targets of miR-378a-3p. Finally, rescue assays revealed that MAPK1 and GRB2 can reverse the effects of miR-378a-3p on chemosensitivity of ovarian cancer cells. In conclusion, miR-378a-3p enhanced the sensitivity of ovarian cancer cells to cisplatin through targeting MAPK1 and GRB2.
Le texte complet de cet article est disponible en PDF.Keywords : miR-378a-3p, MAPK1, GRB2, Cisplatin, Ovarian cancer
Plan
Vol 107
P. 1410-1417 - novembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?